620550-97-2

Basic information

• Product Name: Propanedioic acid, [(2-fluoro-6-nitrophenyl)methyl]-, diethyl ester
• CAS NO: 620550-97-2
• Molecular Formula: C14H16FNO6
• Molecular Weight: 313.283
• Mol File: 620550-97-2.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: Propanedioic acid, [(2-fluoro-6-nitrophenyl)methyl]-, diethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Propanedioic acid, [(2-fluoro-6-nitrophenyl)methyl]-, diethyl ester(620550-97-2)
• EPA Substance Registry System: Propanedioic acid, [(2-fluoro-6-nitrophenyl)methyl]-, diethyl ester(620550-97-2)

Safety Data

• Hazardous Substances Data: 620550-97-2(Hazardous Substances Data)

Upstream product

• 1958-93-6 2-(bromomethyl)-1-fluoro-3-nitrobenzene 
• 105-53-3 diethyl malonate 
• 769-10-8 1-fluoro-2-methyl-3-nitrobenzene 

Downstream Products

• 116434-95-8 5-fluoro-3,4-dihydro-1H-quinolin-2-one 
• 1247021-77-7 2-(2-amino-6-fluoro-benzyl)-malonic acid diethyl ester 
• 132715-74-3 3-(2-Fluoro-6-nitrophenyl)propanoic acid 
• 132715-59-4 3-(2-Fluoro-6-nitro-phenyl)-N,N-dimethyl-propionamide 
• 132715-58-3 3-(2-Fluoro-6-nitro-phenyl)-propionyl chloride 
• 132715-75-4 N,N-Dimethyl-3-(2-amino-6-fluorophenyl)propanamide 

Relevant articles and documents

Triazole derivative having HSP90 (Heat Shock Protein) inhibiting activity, as well as preparation method and application of triazole derivative

The invention discloses a triazole derivative having an HSP90 (Heat Shock Protein) inhibiting activity, as well as a preparation method and an application of the triazole derivative. Specifically, the invention relates to the triazole derivative having a structure as shown in a formula (I), a stereisomer of the triazole derivative and a pharmaceutically acceptable salt, wherein the definition of each substituent group in the formula (I) and the definition in a description are the same. The compound with a novel structure has the HSP90 inhibiting activity, can be used to cure cancers, neurodegenerative disorders, inflammation diseases, autoimmune diseases, ischemic brain injuries and the like, and has a broad application prospect.

NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R15, R16, R17 and n are as described herein, compositions including the compounds and methods of using the compounds.

EP2/4 AGONISTS

EP2/4 compounds having improved dual pharmacological activity are described. The uniqueness of using EP2/4 dual agonists resides in their ability to modify both uveoscleral outflow via the ciliary muscle and conventional outflow via trabecular meshwork and Schlemm's canal all in the same treatment paradigm. The compounds can be employed for the treatment of glaucoma and ocular hypertension. Formula (I).